Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
62.04
-0.82 (-1.30%)
At close: Mar 24, 2026, 4:00 PM EDT
62.63
+0.59 (0.95%)
After-hours: Mar 24, 2026, 7:54 PM EDT
Halozyme Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts that cover Halozyme Therapeutics stock have a consensus rating of "Buy" and an average price target of $78.18, which forecasts a 26.02% increase in the stock price over the next year. The lowest target is $56 and the highest is $92.
Price Target: $78.18 (+26.02%)
Analyst Consensus: Buy
* Price targets were last updated on Feb 19, 2026.
Analyst Ratings
The average analyst rating for Halozyme Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Hold | 4 | 5 | 5 | 5 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 13 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Strong Buy Maintains $75 → $90 | Strong Buy | Maintains | $75 → $90 | +45.07% | Feb 19, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $65 → $75 | Hold | Maintains | $65 → $75 | +20.89% | Feb 19, 2026 |
| TD Cowen | TD Cowen | Strong Buy Maintains $79 → $90 | Strong Buy | Maintains | $79 → $90 | +45.07% | Jan 8, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +45.07% | Dec 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +45.07% | Nov 28, 2025 |
Financial Forecast
Revenue This Year
1.79B
from 1.40B
Increased by 28.24%
Revenue Next Year
2.02B
from 1.79B
Increased by 12.79%
EPS This Year
8.18
from 2.56
Increased by 219.39%
EPS Next Year
10.04
from 8.18
Increased by 22.85%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.9B | 2.1B | |||
| Avg | 1.8B | 2.0B | |||
| Low | 1.7B | 1.9B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 33.4% | 17.9% | |||
| Avg | 28.2% | 12.8% | |||
| Low | 22.4% | 6.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 8.62 | 10.58 | |||
| Avg | 8.18 | 10.04 | |||
| Low | 7.71 | 9.29 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 236.7% | 29.4% | |||
| Avg | 219.4% | 22.8% | |||
| Low | 201.3% | 13.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.